ASX ANNOUNCEMENT

MIDKINE ANTIBODIES EFFECTIVE IN CANCER

- Anti-midkine antibodies reduce tumour growth and spread
- Anti-angiogenic mechanism of action also evident
- Final studies in the programme to determine Cellmid’s clinical direction

SYDNEY, Thursday, 03 October 2013: Cellmid Limited (ASX: CDY) is pleased to advise that it has now completed its several cancer xenograft efficacy and mechanism of action studies using the company’s lead anti-midkine (MK) antibody with compelling results.

The MK antibody treatment slowed primary tumour growth, reduced cancer spread (metastasis) and slowed the formation of new blood vessels (angiogenesis) in different tumour types. These findings complete the Company’s extensive preclinical programme to determine clinical direction for its MK antibodies.

The findings of the current studies have been consistent with the results published recently by an independent research group (Hao, et al. Inhibition of the Growth Factor MDK/Midkine by a Novel Small Molecule Compound to Treat Non-Small Cell Lung Cancer (2013) http://www.ncbi.nlm.nih.gov/pubmed/23976985) and add to the growing evidence of midkine’s importance in cancer.

Since its discovery midkine’s role in cancer has been validated extensively. Approximately 200 peer-reviewed publications have been released on the topic, including four within the last three months. These studies, by multiple research groups around the world, show that MK is a key driver of tumorigenesis in at least 25 different types of cancers, including those of the breast, lung, colorectal, gastrointestinal, liver, pancreatic and brain.

Furthermore, these studies describe multiple mechanisms of action by which MK promotes cancer. Cellmid’s antibodies appear to block several of these mechanisms of action simultaneously.

“The biology of how MK promotes cancer has been well described by dozens of research groups globally,” said Cellmid’s Head of Product Development Darren Jones. “We have postulated for some time that MK antibodies would have anti-cancer activities, via multiple mechanisms of action, and it is pleasing to see this confirmed in our own studies with our proprietary MK antibodies.”

Cellmid’s cancer antibody programme is continuing towards the clinic, targeting a pre-IND meeting in the third quarter of 2014.

End
Contact:
Maria Halasz, CEO
T +612 9221 6830
@mariahalasz
**Cellmid Limited (ASX: CDY)**

Cellmid is an Australian biotechnology company developing innovative novel therapies and diagnostic tests for inflammatory diseases and cancer. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to midkine and midkine antagonists globally. The Company’s most advanced development programs involve using its anti-midkine antibodies for the treatment of cancer and inflammatory diseases. In addition, Cellmid is commercialising midkine as a biomarker for cancer diagnosis. Elevated midkine concentration in the blood and other body fluids is strongly indicative of cancer. For further information please see [www.cellmid.com.au](http://www.cellmid.com.au).

**Midkine (MK)**

Midkine is a multifunctional growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is barely detectable in healthy adults and only occurs as a consequence of the pathogenesis of a number of different disorders. Midkine expression is often evident very early in disease onset, even before any apparent physical symptoms. Accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases. Finally, because midkine is only present in a disease context, targeting midkine does not harm normal healthy tissues.